Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 4Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Diabetes Mellitus, Insulin-Dependent, 12 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Meningioma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

lutetium Lu 177 dotatate 2Specimen Handling 2Magnetic Resonance Spectroscopy 2pembrolizumab 1olaparib 1gallium Ga 68 dotatate 1fludarabine 1Surgical Procedures, Operative 1Semaxinib 1Radiosurgery 1Proton Therapy 1Nivolumab 1Lysine 1Ipilimumab 1Interleukin-2 1Imatinib Mesylate 1Ga(III)-DOTATOC 1Erlotinib Hydrochloride 1Cyclophosphamide 1Crossing Over, Genetic 1CTLA-4 Antigen 1Arginine 164Cu-SARTATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1177Lu-DOTA-JR11 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Meningioma × CTLA-4 Antigen × Clear all
NCT03604978 2026-05-13

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
38 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡